GlobeStar Therapeutics Corporation
GlobeStar Therapeutics Corporation
Your view on GSTC
Overview
What the company does, where it operates, and who runs it.
About GlobeStar Therapeutics Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James C. Katzaroff
- Headquarters
- 719 Jadewin Avenue, Richland, WA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James C. Katzaroff
- Headquarters
- 719 Jadewin Avenue, Richland, WA, US
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021.
The company was incorporated in 2016 and is based in Richland, Washington.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for GlobeStar Therapeutics Corporation, and the rating behind it. GSTC last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for GlobeStar Therapeutics Corporation. Starting points for GlobeStar Therapeutics Corporation: beta 1.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for GlobeStar Therapeutics Corporation. GlobeStar Therapeutics Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for GlobeStar Therapeutics Corporation. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for GlobeStar Therapeutics Corporation. GlobeStar Therapeutics Corporation has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
GlobeStar Therapeutics Corporation valued side by side against its closest peers. GlobeStar Therapeutics Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold GlobeStar Therapeutics Corporation, and how their positions are changing. At a $124,111 market value, institutional positions materially move GlobeStar Therapeutics Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by GlobeStar Therapeutics Corporation executives and directors. Shares of GlobeStar Therapeutics Corporation have traded between $0.0001 and $0.0003 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming GlobeStar Therapeutics Corporation. GlobeStar Therapeutics Corporation is a $124,111 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming GlobeStar Therapeutics Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for GlobeStar Therapeutics Corporation. Coverage tracks GlobeStar Therapeutics Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.